# Amla Lipid Profile Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/amla-lipid-profile-meta-analysis-evidence-review
Category: evidence-review
Summary: Amla Lipid Profile Meta-analysis has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed 
Last reviewed: 2026-07-06
Reviewed by: Migaku Evidence Review
# Amla Lipid Profile Meta-analysis: What the Evidence Says

## Quick Answer

Amla Lipid Profile Meta-analysis has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Potential synergistic antihyperglycemic effects of co-supplemental Amla and Olive extracts in hyperlipidemic adults with prediabetes and type 2 diabetes: results from a real-life clinical study | research article | 4 | 2024-10-03 | 10.3389/fnut.2024.1462292 |

## What The Sources Report

- Hyperglycemia and type 2 diabetes mellitus (T2DM) are significant risk for cardiovascular diseases (CVD) in individuals with hypercholesterolemia, potentially leading to coronary artery disease, stroke, and other complications. [Michel P. Hermans (2024); evidence level 4]
- Although statin therapy lowers low-density lipoprotein cholesterol (LDL-C) and reduces CVD risk, it is associated with an increased risk of incident prediabetes and T2DM. [Michel P. Hermans (2024); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For amla lipid profile meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Michel P. Hermans (2024). Potential synergistic antihyperglycemic effects of co-supplemental Amla and Olive extracts in hyperlipidemic adults with prediabetes and type 2 diabetes: results from a real-life clinical study. DOI: 10.3389/fnut.2024.1462292. PMCID: PMC11484402. PMID: 39421612. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC11484402/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.